• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Cerebral venous thrombosis in patients with autoimmune disease, hematonosis or coronavirus disease 2019: Many familiar faces and some strangers
CONCLUSION: A systematic understanding of particular risk factors that should not be neglected when unconventional cerebral venous thrombosis occurs and for a scientific understanding of pathophysiological mechanisms, clinical diagnosis, and treatment, thus contributing to knowledge on special types of venous stroke.PMID:37365966 | DOI:10.1111/cns.14321
Source: CNS Neuroscience and Therapeutics - June 27, 2023 Category: Neuroscience Authors: Yifan Zhou Huimin Jiang Huimin Wei Xuechun Xiao Lu Liu Xunming Ji Chen Zhou Source Type: research

Serious neurological adverse events following immunization against SARS-CoV-2: a narrative review of the literature
Ther Adv Drug Saf. 2023 May 21;14:20420986231165674. doi: 10.1177/20420986231165674. eCollection 2023.ABSTRACTAmid the coronavirus disease 2019 (COVID-19) pandemic, massive immunization campaigns became the most promising public health measure. During clinical trials, certain neurological adverse effects following immunization (AEFIs) were observed; however, acceptable safety profiles lead to emergency authorization for the distribution and use of the vaccines. To contribute to pharmacovigilance and lessen the potential negative impact that vaccine hesitancy would have on immunization programs, we conducted a review of the...
Source: Adv Data - May 24, 2023 Category: Epidemiology Authors: Sara Eslait-Olaciregui Kevin Llin ás-Caballero David Pati ño-Manjarrés Thomas Urbina-Ariza Juan Fernando Cediel-Becerra Camilo Alberto Dom ínguez-Domínguez Source Type: research

Predictors of Intensive Care Unit Admission in Patients with Confirmed Coronavirus Disease 2019: A Cross-Sectional Study
CONCLUSION: A high index of suspicion for ICU admission should be maintained in patients with positive clinical and laboratory predictive factors.PMID:36117577 | PMC:PMC9445874 | DOI:10.30476/IJMS.2021.89916.2068
Source: Atherosclerosis - September 19, 2022 Category: Cardiology Authors: Naeimehossadat Asmarian Farid Zand Parvin Delavari Vahid Khaloo Zahra Esmaeilinezhad Golnar Sabetian Yaldasadat Moeini Mohsen Savaie Fatemeh Javaherforooshzadeh Farhad Soltani Farid Yousefi Ebrahim Heidari Sardabi Maryam Haddadzadeh Shoushtari Anoush Dehn Source Type: research

Neuroimmune disorders in COVID-19
AbstractSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the aetiologic agent of the coronavirus disease 2019 (COVID-19), is now rapidly disseminating throughout the world with 147,443,848 cases reported so far. Around 30 –80% of cases (depending on COVID-19 severity) are reported to have neurological manifestations including anosmia, stroke, and encephalopathy. In addition, some patients have recognised autoimmune neurological disorders, including both central (limbic and brainstem encephalitis, acute disseminated encephalomyelitis [ADEM], and myelitis) and peripheral diseases (Guillain–Barré and Miller ...
Source: Journal of Neurology - May 20, 2022 Category: Neurology Source Type: research

Recognizing Vaccine-Induced Immune Thrombotic Thrombocytopenia
CONCLUSIONS: Vaccine-induced immune thrombotic thrombocytopenia is a serious complication of vaccination that is not feasible to anticipate or prevent. When the patient presents with sustained headache, neurologic symptoms/signs, abdominal pain, dyspnea, or limb pain/swelling beginning 5–30 days post vaccination, platelet count and d-dimer must be measured, and imaging for thrombosis performed. Confirmation of vaccine-induced immune thrombotic thrombocytopenia diagnosis should be ordered (platelet factor 4/polyanion enzyme-linked immunosorbent assay; platelet factor 4–enhanced platelet activation testing) as treatm...
Source: Critical Care Medicine - December 20, 2021 Category: Emergency Medicine Tags: Online Review Article Source Type: research

COVID ‐19 Outcomes in Patients With Systemic Autoimmune Rheumatic Diseases Compared to the General Population: A US Multicenter, Comparative Cohort Study
ConclusionOur findings indicate that COVID ‐19 patients with systemic ARDs may be at a higher risk of hospitalization, ICU admission, acute renal failure, and venous thromboembolism when compared to COVID‐19 patients without systemic ARDs. These risks may be largely mediated by comorbidities, except for the risk of venous thromboembolism .
Source: Arthritis and Rheumatology - May 1, 2021 Category: Rheumatology Authors: Kristin M. D ’Silva, April Jorge, Andrew Cohen, Natalie McCormick, Yuqing Zhang, Zachary S. Wallace, Hyon K. Choi Tags: Brief Report Source Type: research

Neuropsychiatric Symptoms of COVID-19 Explained by SARS-CoV-2 Proteins ’ Mimicry of Human Protein Interactions
Conclusion: SARS-CoV-2-human protein interactions may lead to the development of delirium, psychosis, seizures, encephalitis, stroke, sensory impairments, peripheral nerve diseases, and autoimmune disorders. Our findings are also supported by the previous in vivo and in vitro studies from other viruses. Further in vivo and in vitro studies using the proteins that are pointed here, could pave new targets both for avoiding and reversing neuropsychiatric presentations.
Source: Frontiers in Human Neuroscience - March 23, 2021 Category: Neuroscience Source Type: research

Late-onset myocardial infarction and autoimmune haemolytic anaemia in a COVID-19 patient without respiratory symptoms, concomitant with a paradoxical increase in inflammatory markers: a case report
ConclusionsBoth complications occurred quite late after COVID-19 diagnosis and were probably precipitated by systemic inflammation, as indicated by a significant delayed increase in inflammatory markers, including interleukin-6 (IL-6).
Source: Journal of Medical Case Reports - December 18, 2020 Category: General Medicine Source Type: research

Impact of COVID-19 on the cerebrovascular system and the prevention of RBC lysis.
Authors: Akhter N, Ahmad S, Alzahrani FA, Dar SA, Wahid M, Haque S, Bhatia K, Sr Almalki S, Alharbi RA, Sindi AAA Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) uses Angiotensin- converting enzyme 2 (ACE2) receptors to infect host cells which may lead to coronavirus disease (COVID-19). Given the presence of ACE2 receptors in the brain and the critical role of the renin-angiotensin system (RAS) in brain functions, special attention to brain microcirculation and neuronal inflammation is warranted during COVID-19 treatment. Neurological complications reported among COVID-19 patients range from mi...
Source: European Review for Medical and Pharmacological Sciences - October 23, 2020 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

Pharmacological and cardiovascular perspectives on the treatment of COVID-19 with chloroquine derivatives.
Abstract The novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19) and an ongoing severe pandemic. Curative drugs specific for COVID-19 are currently lacking. Chloroquine phosphate and its derivative hydroxychloroquine, which have been used in the treatment and prevention of malaria and autoimmune diseases for decades, were found to inhibit SARS-CoV-2 infection with high potency in vitro and have shown clinical and virologic benefits in COVID-19 patients. Therefore, chloroquine phosphate was first used in the treatment of COVID-19 in China. Later, under a lim...
Source: Acta Pharmacologica Sinica - September 22, 2020 Category: Drugs & Pharmacology Authors: Zhang XL, Li ZM, Ye JT, Lu J, Ye LL, Zhang CX, Liu PQ, Duan DD Tags: Acta Pharmacol Sin Source Type: research